Skip to main content
Premium Trial:

Request an Annual Quote

Delta's Reach in the US

The Delta variant of SARS-CoV-2 now accounts for 83 percent of all sequenced COVID-19 cases in the US, CNBC reports.

It adds that Rochelle Walensky, the director of the Centers for Disease Control and Prevention, told Congress Tuesday that this is a dramatic rise from earlier this month when the Delta variant accounted for about half of sequenced COVID-19 cases in the US. She added that in some parts of the US, especially where vaccination rates are low, that percentage is even higher, Business Insider reports.

Walensky also noted that there has been an increase in COVID-19 fatalities, rising to an average 239 deaths per day, according to CNBC. Most deaths, she said, are among unvaccinated individuals, Stat News adds.

The Delta variant is thought to be even more transmissible than the Alpha variant that was itself found to be more transmissible that the original virus, CNBC adds. "The reason it's so formidable is the fact that it has the capability of transmitting efficiently from human to human in an extraordinary manner, well beyond any of the other variants that we've experienced, up to now," Anthony Fauci, the White House chief medical advisor, also said during the hearing, according to CNBC.

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.